Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

424 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment algorithms for high responders: What we can learn from randomized controlled trials, real-world data and models.
Drakopoulos P, Khalaf Y, Esteves SC, Polyzos NP, Sunkara SK, Shapiro D, Rizk B, Ye H, Costello M, Koloda Y, Salle B, Lispi M, D'Hooghe T, La Marca A. Drakopoulos P, et al. Best Pract Res Clin Obstet Gynaecol. 2023 Feb;86:102301. doi: 10.1016/j.bpobgyn.2022.102301. Epub 2022 Dec 27. Best Pract Res Clin Obstet Gynaecol. 2023. PMID: 36646567 Free article. Review.
Comparative effectiveness of gonadotropins used for ovarian stimulation during assisted reproductive technologies (ART) in France: A real-world observational study from the French nationwide claims database (SNDS).
Grynberg M, Cedrin-Durnerin I, Raguideau F, Herquelot E, Luciani L, Porte F, Verpillat P, Helwig C, Schwarze JE, Paillet S, Castello-Bridoux C, D'Hooghe T, Benchaïb M. Grynberg M, et al. Best Pract Res Clin Obstet Gynaecol. 2023 Jun;88:102308. doi: 10.1016/j.bpobgyn.2022.102308. Epub 2022 Dec 28. Best Pract Res Clin Obstet Gynaecol. 2023. PMID: 36707343 Free article.
Effectiveness of recombinant human follicle-stimulating hormone (r-hFSH): recombinant human luteinizing hormone versus r-hFSH alone in assisted reproductive technology treatment cycles among women aged 35-40 years: A German database study.
Bielfeld AP, Schwarze JE, Verpillat P, Lispi M, Fischer R, Hayward B, Chuderland D, D'Hooghe T, Krussel JS. Bielfeld AP, et al. Best Pract Res Clin Obstet Gynaecol. 2023 Jul;89:102350. doi: 10.1016/j.bpobgyn.2023.102350. Epub 2023 May 11. Best Pract Res Clin Obstet Gynaecol. 2023. PMID: 37320996 Free article. Review.
Correction: Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis.
Venetis CA, Helwig C, Mol BW, Chua SJ, Longobardi S, Orvieto R, Lispi M, Storr A, D'Hooghe T. Venetis CA, et al. Reprod Biol Endocrinol. 2023 Jul 26;21(1):68. doi: 10.1186/s12958-023-01114-5. Reprod Biol Endocrinol. 2023. PMID: 37496043 Free PMC article. No abstract available.
Letter to the editor in response to 'A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose' by P. Barrière, S. Hamamah, E. Arbo, C. Avril, B. Salle, J.-L. Pouly, et al. (J Gynecol Obstet Hum Reprod. 2023;52(1):102510).
Montenegro S, Helwig C, Schwarze JE, Castello-Bridoux C, Marque S, Lispi M, D'Hooghe T. Montenegro S, et al. J Gynecol Obstet Hum Reprod. 2023 Oct;52(8):102640. doi: 10.1016/j.jogoh.2023.102640. Epub 2023 Aug 6. J Gynecol Obstet Hum Reprod. 2023. PMID: 37549879 No abstract available.
Fine-tuning the dose of recombinant human follicle-stimulating hormone alfa to individualize treatment in ovulation induction and ovarian stimulation cycles: a real-world database analysis.
Martini AE, Beall S, Ball GD, Hayward B, D'Hooghe T, Mahony MC, Collares F, Catherino AB. Martini AE, et al. Front Endocrinol (Lausanne). 2023 Sep 1;14:1195632. doi: 10.3389/fendo.2023.1195632. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37727455 Free PMC article.
424 results